FGEN has been granted a new patent
Dec 25, 2024, 11:35 PM
1.52%
What does FGEN do
FibroGen, headquartered in San Francisco, focuses on developing novel therapeutics for cancer and anemia, with key products including Pamrevlumab and Roxadustat. The company went public on November 14, 2014, and employs 486 staff.
FGEN filed a patent for "[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid (roxadustat) for the treatment of chemotherapy-induced anemia (cia)" on Mon, July 31, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.